Roisin E. O’Cearbhaill, MD

Articles by Roisin E. O’Cearbhaill, MD

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer

April 14th 2026

Roisin E. O’Cearbhaill, MD, discussed the MUC16 × CD28 bispecific antibody REGN5668 in treating patients with recurrent ovarian or endometrial cancer.

Using PARP Inhibitors in Advanced Ovarian Cancer

ByRoisin E. O’Cearbhaill, MD

July 15th 2018

The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.

Latest Updated Articles

REGN5668 Combo Yields Preliminary Activity in Recurrent Ovarian/Endometrial Cancer
April 14th 2026
Using PARP Inhibitors in Advanced Ovarian Cancer
July 15th 2018

Trending on CancerNetwork

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

Zenocutuzumab Earns FDA National Priority Voucher in Cholangiocarcinoma

TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)